FPT Retail (FRT) Targets 27% Profit Growth for 2026, Plans 30+ New Advanced Drugs

Overview

FPT Retail (FRT) announced at its 2026 Annual General Meeting (AGM) a target for 27% pre-tax profit growth to VND 1.55 trillion and 16% revenue growth to VND 59.5 trillion for the year. The growth strategy is centered on expanding its Long Chau pharmacy network by 450 outlets and introducing over 30 new advanced drugs for rare and chronic diseases, positioning the company in Vietnam’s high-value pharmaceutical segment.

Key Facts

• FRT targets 2026 net revenue of VND 59.5 trillion, a 16% increase over 2025.
• The company aims for 2026 pre-tax profit of VND 1.55 trillion, representing 27% growth.
• The Long Chau pharmacy chain plans to add 450 new outlets nationwide in 2026 through selective expansion.
• Long Chau expects to introduce over 30 new-generation drugs and advanced treatment solutions to Vietnam in 2026, focusing on rare and severe chronic diseases.
• The company recently partnered with a leading UK pharmaceutical firm to introduce three advanced medical solutions for severe asthma, systemic lupus erythematosus, and atypical hemolytic uremic syndrome on April 12, 2024.
• FRT’s strategy rests on three pillars: expanding the healthcare ecosystem, optimizing system-wide operations, and accelerating technology and data application.

What Happened

FPT Retail (FRT) held its 2026 Annual General Meeting on April 17, 2024, where it approved key business results for 2025 and development directions for 2026. According to the company filing, FRT set specific financial targets for 2026, including net revenue of VND 59.5 trillion and pre-tax profit of VND 1.55 trillion. The company stated that despite global economic uncertainties, it has prepared flexible operational plans and strengthened risk management to maintain prudent but effective growth.

The growth plan is heavily reliant on the strategic expansion of its Long Chau pharmacy chain. FRT outlined that Long Chau will expand by 450 new outlets in 2026 through selective site placement to ensure per-store efficiency. Concurrently, Long Chau will deepen strategic partnerships with leading global pharmaceutical companies to bring modern treatment products and solutions to Vietnam. A key initiative is the planned introduction of over 30 new-generation drugs and advanced treatments for rare and chronic diseases within the year.

Market Context

FPT Retail (FRT) is listed on the Ho Chi Minh City Stock Exchange (HOSE). The stock closed at VND 152 on April 10, 2026, up 1.33% on volume of 412,200 shares. The announcement of ambitious 2026 growth targets, particularly the 27% profit growth projection, comes as the company operates in Vietnam’s competitive retail and healthcare sectors, where pharmacy chains are increasingly focusing on higher-margin specialized drugs and services.

Strategic Significance

The 2026 targets underscore FRT’s strategic pivot towards higher-value healthcare retail through its Long Chau brand. By focusing on introducing over 30 advanced drugs for rare and chronic conditions—a segment with significant treatment costs and historically limited access in Vietnam—FRT is not just expanding store count but elevating its product portfolio. This move aims to capture a larger share of the premium pharmaceutical market, improve margins, and differentiate Long Chau from competitors focused on mass-market over-the-counter products. The strategy aligns with broader trends in Vietnam’s healthcare sector, where demand for specialized treatments is rising.

What to Watch

• Quarterly earnings reports, starting with Q1 2026, to track progress toward the VND 59.5 trillion revenue and VND 1.55 trillion pre-tax profit targets.
• Official announcements regarding the specific partnerships with global pharmaceutical firms for the over 30 new drugs slated for 2026 introduction.
• Monthly or quarterly updates on the rollout of the planned 450 new Long Chau outlets to gauge physical expansion pace.
• Any regulatory filings or updates on the integration of Long Chau with national platforms like VNeID, which could impact customer reach and operational efficiency.